Extra-cavitary primary effusion lymphoma (PEL), often associated with human herpes virus 8 (HHV8) infection, represents a rare and aggressive form of non-Hodgkin lymphoma, which is predominantly found in individuals with severe immunosuppression. As an acquired immunodeficiency syndrome (AIDS)-associated lymphoma, PEL typically manifests in the context of advanced human immunodeficiency virus (HIV) infection, requiring tailored therapeutic approaches to manage both the lymphoma and underlying immunodeficiency. A 53-year-old male patient from Cape Verde presented with a three-day history of fever, night sweats, right iliac fossa pain, hematochezia, and an unintentional weight loss of five kilograms over the previous two months. A laboratory study revealed a previously undiagnosed co-infection with HIV-1 and HIV-2, with a CD4+ T-cell count of 63/μL. The abdominal-pelvic computed tomography (CT) scan revealed hepatosplenomegaly with hypodense nodular lesions and prominent lymph nodes in the celiac-mesenteric, axillary, and cervical regions. Lung imaging showed non-specific nodules. An extensive investigation for opportunistic infections was conducted, with a bronchoalveolar lavage culture test positive for and a colon biopsy indicating Cytomegalovirus colitis. Further histological examination from a gastric biopsy revealed the diagnosis of the solid variant of PEL. The patient initiated treatment for opportunistic infections followed by antiretroviral therapy. However, he experienced multiple complications and due to his deteriorating condition, chemotherapy was not initiated and he ultimately died. This rare clinical case of lymphoma in a patient co-infected with HIV-1 and HIV-2, the first of its kind to be reported, to the authors' knowledge, underscores the diagnostic and therapeutic challenges associated with this condition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694847 | PMC |
http://dx.doi.org/10.7759/cureus.75039 | DOI Listing |
Cureus
December 2024
Infectious Diseases, Hospital Garcia de Orta, Lisbon, PRT.
Extra-cavitary primary effusion lymphoma (PEL), often associated with human herpes virus 8 (HHV8) infection, represents a rare and aggressive form of non-Hodgkin lymphoma, which is predominantly found in individuals with severe immunosuppression. As an acquired immunodeficiency syndrome (AIDS)-associated lymphoma, PEL typically manifests in the context of advanced human immunodeficiency virus (HIV) infection, requiring tailored therapeutic approaches to manage both the lymphoma and underlying immunodeficiency. A 53-year-old male patient from Cape Verde presented with a three-day history of fever, night sweats, right iliac fossa pain, hematochezia, and an unintentional weight loss of five kilograms over the previous two months.
View Article and Find Full Text PDFOpen Forum Infect Dis
January 2025
Viroscience Department, Erasmus MC, Rotterdam, The Netherlands.
Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer inhibitors, particularly dolutegravir, have improved treatment outcomes for people with HIV-2. Lenacapavir, a novel and potent antiretroviral capsid inhibitor, offers additional therapeutic options.
View Article and Find Full Text PDFBioorg Chem
December 2024
Laboratory of Molecular Chemistry, Materials and Environment (LCM2E), Department of Chemistry, Multidisciplinary Faculty of Nador, University Mohamed I, 60700 Nador, Morocco. Electronic address:
Given the ease of synthetic accessibility and the promising biological profile demonstrated by both imidazo[1,2-a]pyridine and Chalcone derivatives, a series of Chalcone-based imidazo[1,2-a]pyridine derivatives were synthesized and characterized using H NMR, C NMR, Mass Spectrometry and FTIR techniques. Density functional theory (DFT) was employed to investigate the structural and electronic properties, providing insights into potential reactive sites. The synthesized compounds were evaluated in vitro for their antiviral properties against human immunodeficiency virus type-1 (HIV-1) and human immunodeficiency virus type-2 (HIV-2) in MT-4 cells.
View Article and Find Full Text PDFClin Infect Dis
December 2024
Université Paris Cité, Inserm, IAME, F-75018, Paris, France.
Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
November 2024
Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.
HIV-2 infection although less virulent compared to HIV-1 is endemic in many parts of West Africa. In Burkina Faso, few data exist on HIV-2 genotypic resistance. The objective of this study was to assess HIV-2 genotypic resistance and viral load in adult patients infected with HIV-2 in Burkina Faso.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!